Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-03

Study Completion Date

2023-03-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This purpose of this study is to assess the feasibility of FLASH radiotherapy for the palliative treatment of painful bone metastases. FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax

NCT05524064

Bone Metastases in the Thorax

ACTIVE_NOT_RECRUITING NA

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy

NCT06859801

Bone Cancer Metastatic

NOT_YET_RECRUITING

Palliative UNConventional Hypofractionation Trial for Metastatic Bone Disease

NCT05115331

Metastatic Bone Tumor

ACTIVE_NOT_RECRUITING PHASE3

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

NCT02145286

Metastatic Bone Lesion

UNKNOWN NA

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

NCT00003162

Breast Cancer Metastatic Cancer Pain +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical investigation is designed to assess the workflow feasibility of FLASH radiotherapy treatment in a clinical setting, as well as the toxicities, and pain relief when used to treat bone metastasis(-es) in the extremities (excluding feet, hands, wrists). FLASH radiotherapy has been shown in preclinical studies to cause less injury to surrounding normal tissues during radiation treatment, while still having similar tumor cell killing. Patients at least 18 years of age with painful bone metastases located in the limbs will be considered for the study. These patients represent an ideal population for a feasibility study of FLASH radiotherapy as they are known to benefit from the palliative effects of radiotherapy using single dose radiation regimens of 8Gy which is what is being used in this investigation. After treatment, patients will be assessed for pain response as well as any adverse side-effects of radiation. The workflow feasibility of the treatment will also be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open label, single arm prospective feasibility study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FLASH radiotherapy for painful bone metastasis(-es)

Group Type EXPERIMENTAL

FLASH Radiotherapy

Intervention Type RADIATION

FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FLASH Radiotherapy

FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient age at least 18 years
* Up to 3 painful bone metastasis(-es) in the extremities
* Bone metastases that can be treated using pre-defined treatment field sizes (7.5 cm x 7.5 cm; 7.5 cm x 10 cm; 7.5 cm x 12 cm; 7.5 cm x 14 cm; 7.5 cm x 16 cm; 7.5 cm x 18 cm; 7.5 cm x 20 cm), without overlap of radiation fields
* Life expectancy of \>2 months (in the judgement of the investigator)
* Patients who are able to comply with the protocol
* Provision of signed and dated informed consent form

Exclusion Criteria

* Prior radiotherapy to the treatment site(s)
* Lesions of the feet, hands, wrists are not eligible treatment sites for FLASH
* More than 3 painful bone metastases of the limbs requiring palliative radiotherapy
* Tumor lysis of \>50% of the circumferential bone cortex, or other factors considered to place the subject at significant risk of pathologic fracture
* Patients with bone fractures and/or metal implants in the treatment field
* Patients who will receive cytotoxic chemotherapy within 1 week prior to or 1 week following their planned radiation treatment
* Prior local therapy modality to the treatment site(s) within 2 weeks of study enrollment
* Patients with pacemakers or other implanted devices at risk of malfunction during radiotherapy
* Patients with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation
* Patients at known risk of enhanced normal tissue sensitivity to radiotherapy due to inherited predisposition or documented comorbidity that might lead to hypersensitivity to ionizing radiation
* Patients enrolled in any other clinical studies the investigator believes to be in conflict with this clinical investigation.
* Patients who are pregnant or nursing

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No